Susquehanna International Group, LLP Acorda Therapeutics Inc Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.55 - $1.0 $107,667 - $195,759	195,759 Added 848.51%	218,830 $129,000
Q4 2022 Feb 14, 2023	SELL	$0.52 - $0.77 $1,134 - $1,680	-2,182 Reduced 8.64%	23,071 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $0.53 $5,981 - $10,932	-20,627 Reduced 44.96%	25,253 $8,000
Q2 2022 Aug 15, 2022	BUY	$0.3 - $1.67 $3,009 - $16,750	10,030 Added 27.98%	45,880 $21,000
Q3 2021 Nov 15, 2021	SELL	$3.36 - $4.79 $16,178 - $23,063	-4,815 Reduced 11.84%	35,850 $165,000
Q2 2021 Aug 11, 2021	SELL	$3.61 - $5.23 $173,164 - $250,872	-47,968 Reduced 54.12%	40,665 $194,000
Q1 2021 May 17, 2021	BUY	$3.8 - $8.04 $336,805 - $712,609	88,633 New	88,633 $432,000

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.